The American Cancer Society has estimated that in 2009 more than 192,280 men will be diagnosed with prostate cancer, 27,360 men will die of prostate cancer, and 1 in 6 men will be affected by this disease over their lifetime. Commonly used diagnostic tests have been shown to have high false positive and false negative rates. In addition, transrectal ultrasound-guided biopsies are essentially blind and random and they can miss at least 20 percent of cancer.

"MRI with dynamic contrast enhancement provides a more accurate image of the prostate gland for a more thorough diagnostic assessment," said Stacey Stevens, Senior Vice President of Marketing and Strategy for iCAD. "A necessary component to this technology is computer-aided detection (CAD) which uses advanced algorithms to help radiologists determine malignant from benign tissues and to pinpoint the tumor location and size."


Quantitative image analysis and review software (iCAD's VividLook) technology provides a means of visualizing the presence and patterns of suspicious lesions among the images taken by MRI and obtaining the quantitative results of key physiological parameters to allow the users to discern the different contrast enhancement profiles in malignant versus benign tissues.

About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company's first breast cancer detection product in 2002, over 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD's solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.


Back to HCB News